Browse Articles

Discover research articles across all indexed journals

Study on bearing strength of fiber reinforced polymer anchoring cable in deep roadway

Scientific Reports Lei Wang, Yilin Wu, Dongmei Chen et al. Feb 10, 2025 DOI: 10.1038/s41598-025-85584-0

A comparative analysis of complication rates in urinary diversions: Exploring the impact of contemporary surgical trends.

Journal of Clinical Oncology John Pfail, Melinda Fu, Rachel Passarelli et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.751

751 Background: Historically, outcomes have been similar among patients undergoing continent (CD) and incontinent diversion (ID) at time of radical cystectomy (RC), with no difference in complication rates. Given the decreasing rates of CD, we sought to examine postoperative complication rates based on type of diversion in a contemporary cohort. Methods: Data was extracted from the NSQIP database from 2019-2021 who underwent RC. Patients were stratified based on diversion type. Statistical endpoints included thirty-day complications, length of stay (LOS), and readmissions. Optimal RC outcome was defined as absence of any postoperative complication, reoperation, prolonged LOS (75th percentile, 8 days) with no readmission. Multivariable analyses with Bonferroni correction were performed to assess the association between urinary diversion and postoperative outcomes. Results: A total of 4375 patients were identified, including 3780 (86.4%) who underwent ID and 595 (13.6%) who underwent CD. Compared to patients with CD, those with ID were more likely to be older, female, have higher ASA, worse renal function, robotic/lap approach, history of radiation or pelvic surgery, and higher stage (Table). On multivariable analysis, after Bonferroni adjustment, patients with CD had increased odds of high grade complications (OR 1.58; 99% CI [1.15-2.15]) and readmission (OR 1.7 [1.28-2.27]) as well as lower odds of an optimal outcome (OR 0.74 [0.58-0.95]) compared to incontinent diversion. Conclusions: In a contemporary cohort of patients undergoing RC, odds of adverse postoperative outcomes were increased among those undergoing CD compared to ID, despite more favorable baseline characteristics in this cohort. Preoperative and operative characteristics for patients undergoing radical cystectomy procedures stratified by diversion type. Incontinent Continent P-value Characteristic N=3780 N=595  Age 72.0 [65.0;77.0] 63.0 [57.0;69.0] <0.001  Sex: 0.001 Female 734 (19.4%) 80 (13.4%) Male 3046 (80.6%) 515 (86.6%) Year of Surgery: 0.33  2019 1450 (38.4%) 240 (40.3%)  2020 1601 (42.4%) 255 (42.9%)  2021 729 (19.3%) 100 (16.8%) ASA: <0.001  <3 752 (19.9%) 185 (31.1%)  ≥3 3028 (80.1%) 410 (68.9%) eGFR 68.3 [51.8;87.3] 77.3 [62.7;92.8] <0.001 BMI 27.8 [24.7;31.6] 27.5 [24.9;31.1] 0.704 Chemotherapy 1320 (34.9%) 276 (46.4%) <0.001 Radiation 346 (9.15%) 22 (3.70%) <0.001 Prior Pelvic Surgery 1863 (49.3%) 258 (43.4%) 0.008 Surgical Approach: <0.001  Open 2672 (70.7%) 467 (78.5%)  Hybrid 185 (4.89%) 20 (3.36%)  Lap/Robo 923 (24.4%) 108 (18.2%) OR Time 312 [240;393] 369 [280;465] <0.001 # Nodes 16.0 [10.0;25.0] 17.0 [11.0;26.5] 0.001 AJCC Stage: <0.001  0a-II 1833 (48.5%) 370 (62.2%)  III-IV 1947 (51.5%) 225 (37.8%) ASA: American Society of Anesthesiologist classification. BMI: body mass index. OR: operating room. AJCC: American Joint Committee on Cancer. # of nodes: median, [IQR].

Whole-slide multiplexed tissue imaging of prostate adenocarcinoma to investigate immune niches in high- versus low-grade tumors.

Journal of Clinical Oncology Ali Amiryousefi, Jeremiah Wala, Brian William Labadie et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.224

224 Background: The tumor-immune microenvironment (TME) is crucial in the progression of prostate cancer (PCa), yet little is known about its spatial organization and immune composition in treatment-naïve, localized PCa. While immunotherapy has had limited success in metastatic PCa, its efficacy in localized disease remains largely unknown. This study aims to dissect tumor-immune interactions in primary PCa and explore differences in immune landscape between low- and high-Gleason PCa, thus providing biologic insights for immunotherapy actionability. Methods: We performed spatial profiling of radical prostatectomy (RP) specimens from 28 treatment-naïve prostate cancer patients. These included 14 patients with low-grade disease (Gleason Grade Group 1–2) and 14 patients with high-grade disease (Gleason Grade Group 4–5). Using multiplex cyclic immunofluorescence (CyCIF) and a 27-marker panel, we obtained single-cell resolution across whole-slide images. Tumor and stromal compartments were manually annotated, and immune cell densities and neighborhood were analyzed and compared between low- and high-grade tumors. Spatial analysis focused on identifying immune clusters (IC -suggestive of tertiary lymphoid structures -TLS) and quantified the degree of immune infiltration along with characterization of T cell exhaustion markers such as CD8+PD1+TCF1+ cells. Results: High-grade tumors exhibited significantly higher infiltration of CD8+ T cells and CD20+ B cells compared to low-grade tumors. Spatial profiling revealed organized ICs, especially in high-grade tumors, which exhibited characteristics consistent with TLS. These ICs were enriched with precursor-exhausted CD8+PD1+TCF1+ T cells (TPEX), suggesting a state of immune exhaustion that may be therapeutically reactivatable. The presence of TLS and immune exhaustion markers in high-grade tumors highlights a more active immune microenvironment than previously appreciated in primary prostate cancer. Conclusions: Our findings reveal that a subset of high-grade prostate cancers harbor an organized, immune-infiltrated tumor microenvironment, including adaptive immune features such as TLS and CD8+ T cell exhaustion. These immune landscapes, marked by significant CD8+ and CD20+ cell infiltration and spatial clustering, suggest that high-grade prostate tumors may be amenable to immune-based therapies, despite the failure of immune checkpoint blockade in metastatic PCa. These results raise the hypothesis that immunotherapy might be effective in treatment-naïve high-grade prostate cancer. Future efforts should explore whether these immune profiles can be leveraged for risk stratification or as biomarkers for response to immunotherapy in advanced disease.

Impact of perioperative acute kidney injury on future renal outcomes in patients who undergo radical cystectomy: A multi-institutional retrospective cohort study.

Journal of Clinical Oncology Naoki Fujita, Shogo Hosogoe, Toshikazu Tanaka et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.879

879 Background: Acute kidney injury (AKI) is one of the frequent complications in patients who undergo radical cystectomy (RC). Although AKI has been reported to have a negative impact on renal outcomes in several diseases, the impact of perioperative AKI on major adverse kidney events (MAKE) in patients who undergo RC remains unclear. Methods: This multi-institutional retrospective cohort study included 702 patients with muscle invasive bladder cancer who underwent RC. AKI was defined according to the KDIGO criteria. Patients were divided into two groups: patients who developed AKI after RC (AKI group) and patients who did not (non-AKI group). MAKE was a composite of sustained ≥50% decline in eGFR, doubling of serum creatinine from the baseline, and sustained decrease in eGFR to <15 ml/min/1.73m 2 . The laterality and grade of hydronephrosis at the time of MAKE onset or last follow-up were evaluated. Multivariable Cox-proportional hazards regression analysis was performed to evaluate the impact of perioperative AKI on MAKE-free survival. Results: The median age and follow-up period were 70 years and 48 months, respectively. Of the 702 patients, 368 (52%) developed AKI after RC, with 26% having severe AKI (stage 2-3). Significant declines in eGFR at one-, three, and five-year after RC were observed in the AKI group compared with those in the non-AKI group ( P <0.001, P <0.001, and P <0.001, respectively). MAKE-free survival in the AKI group was significantly shorter than that in the non-AKI group ( P <0.001). After adjustment for confounding variables, including age, comorbidity, preoperative renal function, and hydronephrosis, AKI was independently and significantly associated with shorter MAKE-free survival (Table). Conclusions: Perioperative AKI had a negative impact on future renal outcomes in patients who underwent RC. Multivariable analysis for MAKE-free survival. Factor P value Hazard ratio 95% CI Age Continuous 0.730 1.005 0.978–1.033 Body mass index Continuous 0.051 1.068 1.000–1.142 Hypertension Presence 0.454 1.182 0.762–1.834 Dyslipidemia Presence 0.187 1.397 0.850–2.296 Diabetes mellitus Presence 0.370 1.257 0.762–2.072 Preoperative eGFR Continuous 0.146 0.990 0.977–1.003 Grade of hydronephrosis Continuous <0.001 1.509 1.206–1.888 Laterality of hydronephrosis Bilateral 0.301 0.734 0.409–1.318 AKI Positive 0.003 1.932 1.254–2.977

The role of peer support in coping and adjustment to dialysis and transplantation: Study protocol

PLoS ONE Anna Winterbottom, Eleri Wood, Andrew Mooney et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0318124

Introduction People with kidney failure receiving dialysis or kidney transplantation find it difficult to adapt to treatment related routines and restrictions, and feel frustrated when their expectations aren’t matched by their lived experience. Health professionals provide information to help people prepare for kidney treatments, but it may be that ‘peer supporters’ - people who live with kidney disease - can provide more easily understood and relevant information. This study will explore how learning from peer supporters might improve the experience of treatment, after dialysis initiation and post-transplantation, by helping them to better understand what to expect from treatments. Methods Two mixed methods studies including in-depth interviews and questionnaires. In each study, participants will be recruited at two timepoints, before commencing dialysis or transplantation, and 6 months later. Questionnaires and interviews will explore expectations and the lived experience of treatment, and if peer support impacts on adjustment and coping with treatment. Participants will be recruited from two large teaching hospitals in the North and South of England, where one has access to a formal kidney peer support program. Discussion Delivering peer support in kidney units is increasingly popular, yet provision is inconsistent and generally low quality. Providing an evidence base for it’s use will help guide the optimal development of peer support programmes and efficient allocation of peer resources. A report will be produced to summarise the our findings, which will help kidney units better help people with kidney failure prepare for kidney treatments.

A novel method for detecting SARS-CoV-2 IgM and IgG based on the gold immune chromatography assay

Scientific Reports Xiaoqin Yao, Hao Xu, Qin Du et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89012-1

Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting.

Journal of Clinical Oncology Cherrishe Brown-Bickerstaff, Paul R. Conkling, Rosa Banuelos et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.470

470 Background: Multiple approved immunotherapy (IO)-based combination regimens have demonstrated efficacy as first-line (1L) tx for mRCC, but have also shown notable toxicity. These factors may lead to variations in how tx regimens are used in RW community oncology care. No direct, prospective comparison exists for FDA-approved IO-IO or IO + tyrosine kinase inhibitor (IO-TKI) combination regimens in mRCC. This study assessed 1L TKI dosing patterns and RW outcomes of pts with mRCC in a large network of US community oncology practices. Methods: A retrospective, observational, matched cohort study was conducted among pts diagnosed with mRCC in The US Oncology Network IKnowMed electronic health record database. Eligible pts were ≥21 years old at initial diagnosis; initiated 1L tx in the metastatic setting with an IO-IO (ipilimumab [ipi] + nivolumab [nivo]) or IO-TKI (nivo + cabozantinib [cabo], pembrolizumab [pem] + axitinib [axi], or pem + lenvatinib [len]) combination regimen between Jan 1, 2021 and Apr 30, 2023; and had ≥1 post-treatment visit or a record of death during the study observation period (Jan 1, 2021 – Oct 31, 2023). Across cohorts, pts were exactly matched on IMDC risk score, sex, and age (<60y or ≥60y). Initial TKI dosing prescribed was summarized descriptively. Time to next treatment (TTNT) and overall survival (OS) were analyzed using the Kaplan-Meier method and univariable Cox regression. Results: A total of 308 pts, 77 in each cohort, were included with a median follow-up time of 11.0, 14.1, 8.8, and 9.2 months (mo) in the ipi + nivo, nivo + cabo, pem + axi, and pem + len cohorts, respectively. Across cohorts, 64% were male, 75% were ≥60 years of age (mean age, 65.1-66.9y), and IMDC risk score was as follows: 18% favorable, 51% intermediate, 21% poor, and 10% unknown. RW TKI dosing patterns and efficacy outcomes are described in the table.More pts initiated len (29.9%) below the recommended dose relative to cabo (15.6%) and axi (11.7%). The nivo + cabo cohort had a numerically longer median TTNT (14.3 mo) compared with the pem + axi (10 mo) and pem + len (9.4 mo) cohorts. Conclusions: TTNT analysis in a matched population suggests benefit of nivo + cabo in pts with mRCC in the RW 1L setting compared with other IO-TKI combinations. Dosing patterns suggest more pts may start len below the recommended dose relative to other TKIs. The highest 12-month OS was observed with nivo + cabo; however, additional follow-up is needed for more mature OS data. RW TKI dosing patterns and efficacy outcomes in 1L mRCC. IO-IO IO-TKI IO-TKI IO-TKI Variable Ipi + Nivo n=77 Nivo + Cabo n=77 Pem + Axi n=77 Pem + Len n=77 Initiated TKI below label recommended dose, n (%) NA 12 (15.6) 9 (11.7) 23 (29.9) Median TTNT, mo (95% CI) 8.4 (5.9-14.5) 14.3 (11.3-25.8) 10.0 (6.8-13.4) 9.4 (6.9-13.5) Hazard ratio (95% CI) 1.45 (0.96-2.18) ref 1.58 (1.04-2.38) 1.57 (1.04-2.37) 12-month OS estimate, mo 66.3 76.8 66.9 64.8

Patterns of split-dose gemcitabine and cisplatin (GC) use in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a 10-country physician survey.

Journal of Clinical Oncology Richard Thomas O'Dwyer, Sophia Junker, Robert Szulkin et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.699

699 Background: Gemcitabine + cisplatin (GC) is a highly effective treatment for la/mUC. For patients who are ineligible for standard GC, split-dose GC is a promising alternative. This study aimed to provide insights into the use of split-dose GC and factors influencing treatment choice across 10 countries. Methods: Between January and March 2024, an international cross-sectional study was conducted via an online survey of physicians treating patients with la/mUC in Australia, Brazil, Canada, France, Germany, India, Italy, Spain, the UK, and the US. Demographics, practice patterns, and clinical parameters influencing treatment choice were collected. Multivariate logistic regression was used to determine factors influencing the use of split-dose GC. Results: The study included 791 physicians, mostly male (73%), who had a mean age of 43 years and an average of 13.2 years in practice, with 59% in academic practice. Most (85%) reported using split-dose GC across different treatment settings, including in 41% in neoadjuvant treatment, 40% in adjuvant treatment, and 43% in the metastatic setting. Physicians with the following characteristics were more likely to use split-dose GC: longer time in practice (per 10 years: odds ratio [95% CI], 1.58 [1.18-2.16]), higher patient volume (per 10 patients: 1.06 [1.01-1.14]), and public vs private practice (1.94 [1.27-2.97]). The preferred schedule in la/mUC was GC 35 mg/m 2 on days 1+8 of a 21-day cycle (57%). Most physicians (80%) used avelumab maintenance treatment after split-dose GC in patients without progression. The table shows acceptable lower thresholds for creatinine clearance (CrCl) reported by physicians for patients receiving split-dose GC. Conclusions: This large international survey underscores the extensive use of split-dose GC as an alternative regimen for patients with la/mUC who are ineligible for standard GC. Physicians who are more experienced and manage more patients are more likely to use split-dose GC. The results highlight the need for evaluating split-dose GC prospectively and establishing consensus guidelines for optimal use of split-dose GC in clinical practice and clinical trials. Physiciansn=635 CrCl in patients with ECOG performance status 0-1, n (%) 50 mL/min 573 (90.2) 40 mL/min 407 (64.1) 30 mL/min 195 (30.7) CrCl in patients with ECOG performance status 2, n (%) 50 mL/min 443 (69.8) 40 mL/min 290 (45.7) 30 mL/min 119 (18.7)

Comparing progression following systemic and tumor-directed therapy for <i>de novo</i> versus recurrent PSMA PET–defined oligo-M1 prostate cancer: A pooled analysis of SOLAR and SATURN clinical trials.

Journal of Clinical Oncology Jesus Eduardo Juarez Casillas, John Nikitas, Matthew Rettig et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.64

64 Background: Therapeutic strategies for oligometastatic castration sensitive prostate cancer (omCSPC) combining treatment of the primary and metastases with short-term intensified systemic therapy aim to improve survival and local control while minimizing toxicity from indefinite systemic therapy. This post-hoc analysis of the SOLAR (NCT03298087) and SATURN (NCT03902951) trials, which evaluated systemic and tumor-directed therapy in PSMA-PET defined oligo-M1 (≤5 metastases) de novo and recurrent omCSPC, respectively, aims to draw inferences on biology and oncologic outcome. Methods: All patients were treated with 6 months of systemic therapy: leuprolide, abiraterone acetate with prednisone, and apalutamide in conjunction with SBRT to oligometastatic sites. SOLAR patients were treatment naïve and underwent either radical prostatectomy (RP) with lymph node dissection followed by post-operative radiotherapy for high-risk features, or definitive radiotherapy (dRT). SATURN patients all had recurrent disease after RP with or without postoperative radiotherapy and may have also had prior hormone or metastasis-directed therapy. The primary endpoint (response rate) was the percentage of patients with an undetectable PSA (&lt;0.05 ng/mL) for post-RP patients, or a PSA &lt;2 ng/mL for post-dRT patients, six months after recovery of testosterone to &gt;150 ng/dl. Secondary endpoints included progression-free survival (PFS) and eugonadal PFS starting from time of testosterone recovery. Kaplan-Meier assessed differences in time-to-event endpoints from initiation of systemic therapy. Fischer’s Exact Test compared proportional outcomes. Results: Analysis included data from 24 SOLAR and 26 SATURN patients. Overall, median follow-up was 32 months (interquartile range 28.25-36.75 months). Response rates were higher for de novo versus oligorecurrent patients (20/24 [83%] versus 13/26 [50%], p=0.018). PFS and eugonadal PFS were also significantly longer (median not reached versus 17 months and median not reached versus 13 months, respectively, p&lt;0.05). PFS was shorter for oligorecurrent patients with prior exposure to hormone therapy (median 10 months versus not reached, p&lt;0.05). There was no PFS difference comparing patients treated in the de novo setting versus the recurrent setting who were naive to hormonal therapy (p=0.23). Conclusions: Patients with recurrent omCSPC PSMA-PET defined M1 disease had a worse response rate and shorter PFS following intensified systemic and metastasis-directed SBRT than those with de novo omCSPC. The difference was driven by recurrent patients with prior exposure to hormonal therapy, suggesting a continuum of treatment resistances over repeated courses of hormonal therapy. The majority of patients with de novo omCSPC remain in remission after gonadal recovery. Clinical trial information: NCT03298087 , NCT03902951 .

Hydrogeochemical and isotopic analysis for interpreting the formation of the complex geothermal system in the Guide Basin, Northeastern Tibetan Plateau

PLoS ONE Yude Lei, Zhen Zhao, Guangxiong Qin et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0317694

The Guide Basin, located in the northeastern Tibetan Plateau, is rich in geothermal resources. However, whether the genesis of all geothermal waters in the basin is consistent remains an unresolved question. To clarify the geothermal system in this area, this study investigated the hydrogeochemical and isotopic characteristics of geothermal waters, combined with an analysis of the distribution and properties of regional faults. The study analyzed the processes controlling the chemical composition of thermal waters and the reservoir temperatures, ultimately creating a conceptual model of geothermal fluids. The results indicate that the geothermal waters in the Luohantang and Zhacanggou areas are classified as Na-SO4·Cl type, while those in the Xinjie area are classified as Na-HCO3 and Na-HCO3·Cl type. The chemical composition of geothermal waters is primarily controlled by the weathering of silicates, with some influence from carbonate dissolution and cation exchange processes. Isotope data (δD, δ18O, and 87Sr/86Sr) indicate that all geothermal waters originate from atmospheric precipitation and undergo deep circulation. The heat source in Guide Basin comes from mantle heat flow and granite radioactive decay, but the thermal storage patterns in the three regions of the basin are different. The use of cation and silica geothermometers estimates the reservoir temperatures in the basin to range between 82.4 °C and 229 °C. This study enhances the understanding of the genesis of geothermal resources in the northeastern Tibetan Plateau and provides important information for guiding future geothermal exploration in the area.

Mechanisms of carbon and nitrogen distribution in soil aggregates in response to soil conditioners

Scientific Reports Xin Fan, Yuhong Gao, Yifan Wang et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89526-8

Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.

Journal of Clinical Oncology Matthew I. Milowsky, Matthew D. Galsky, Johannes Alfred Witjes et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.658

658 Background: In the phase 3, randomized, double-blind CheckMate 274 trial, adjuvant NIVO demonstrated statistically significant and clinically meaningful disease-free survival (DFS) benefit vs PBO in pts with high-risk MIUC after radical surgery (RS) ± prior neoadjuvant cisplatin-based chemotherapy (NAC). With extended 3-y median follow-up, continued improvements in DFS were seen with NIVO vs PBO in the primary efficacy populations (intent-to-treat [ITT], tumor programmed death ligand 1 [PD-L1] expression ≥ 1%) and in pts with MIBC. Early trends in interim OS favored NIVO vs PBO in ITT and tumor PD-L1 ≥ 1% pts. Here we report additional efficacy outcomes for pts with MIBC. Methods: Pts were randomized 1:1 to NIVO 240 mg every 2 wk or PBO for ≤ 1 y of adjuvant treatment, stratified by tumor PD-L1 expression, nodal status, and prior NAC. Primary endpoints were DFS in ITT and tumor PD-L1 expression ≥ 1% pts. OS in ITT and PD-L1 ≥ 1% pts was a secondary endpoint. Analysis of MIBC pts was exploratory. MIBC OS data are from preplanned interim analyses of ITT and PD-L1 ≥ 1% pts. OS follow-up is ongoing as the prespecified statistical boundaries for significance in ITT and PD-L1 ≥ 1% pts were not crossed at the time of these analyses. Results: Of 709 randomized pts (ITT), 560 (79%) had MIBC (NIVO, n = 279; PBO, n = 281); 284 (51%) of MIBC pts had prior NAC. With median follow-up of 36.1 mo (ITT), DFS improvement with NIVO vs PBO was consistent between all pts with MIBC (hazard ratio [HR] 0.63) and those with (HR 0.58) and without prior NAC (HR 0.69; Table). For OS, HRs favored NIVO vs PBO in all pts with MIBC (HR 0.70) and the tumor PD-L1 ≥ 1% subgroup (HR 0.48), as well as in pts with MIBC with (HR 0.74) and without prior NAC (HR 0.67). Safety was consistent with previous data in ITT pts; no new safety signals were identified. Conclusions: With 3-y median follow-up, consistent benefit in DFS was observed with NIVO vs PBO in all MIBC pts and across prior NAC subgroups. The HR for OS favored NIVO in all MIBC pts, in those with PD-L1 ≥ 1%, and regardless of prior NAC status. These results continue to support adjuvant NIVO as a standard of care for high-risk MIUC and MIBC, potentially providing an opportunity for a curative outcome. Clinical trial information: NCT02632409 . NIVOn NIVOMedian(95% CI), mo PBOn PBOMedian(95% CI), mo HR (95% CI) DFS All MIBC 279 25.6 (19.2–41.8) 281 8.5 (7.3–13.7) 0.63 (0.51–0.78) With prior NAC 142 19.6 (15.6–48.2) 142 8.3 (5.6–11.2) 0.58 (0.43–0.79) No prior NAC 137 25.9 (19.2–51.5) 139 13.7 (7.8–22.1) 0.69 (0.50–0.94) OS All MIBC 279 NR (45.0–NE) 281 39.9 (29.8–52.1) 0.70 (0.55–0.90) PD-L1 ≥ 1% 113 NR (NE–NE) 117 37.6 (26.9–NE) 0.48 (0.29–0.77) With prior NAC 142 55.2 (41.8–NE) 142 40.2 (28.8–53.7) 0.74 (0.53–1.03) No prior NAC 137 NR (40.7–NE) 139 37.7 (28.7–65.2) 0.67 (0.47–0.95) NE, not estimable; NR, not reached.

Updated results of the Tide-A study evaluating avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients with metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology Daniela Arduini, Chiara Ciccarese, Alessandro Acunzo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.551

551 Background: Combinations of therapies with VEGFR-TKI (TKI) and anti-PD1/PDL1 immunotherapy (IO) are considered the standard of care for first line treatment of patients (pts) with mRCC. The Tide-A trial previously reported the feasibility of TKI interruption and immunotherapy maintenance in pts achieving tumor response after TKI+IO combination, achieving its primary endpoint. Here we reported the updated results with a longer follow-up. Methods: Pts with surgery for primary tumor, without symptomatic/bulky disease or liver mets, were treated with Ave 800 mg flat dose IV Q2W + Axi 5 mg PO BID for 36 weeks (W). At W36, pts who achieved partial response (PR) interrupted Axi and continued Ave until progression of disease (PD) or unacceptable toxicity. In case of PD while on Ave, Axi was restarted and interrupted again in case of new PR. Pts without PR at W36 continue the combo until PD. Here we reported the updated results for mPFS and mOS in the overall population and in those pts who interrupted Axi. The outcome after Axi reintroduction was also described. Results: 75 pts were evaluated in the efficacy analysis (40% favorable risk, 60% intermediate/poor risk). At the cutoff data Apr 2024, after a median follow up of 31.7 mos, the mPFS was 27.9 mos (95%CI, 23.0 - 32.8) while the mOS was not reached and the 24-mos OS rate was 85%. The median duration of 1 st avelumab maintenance was 16 weeks. Among the 29 pts who interrupted Axi at W36, the mPFS and the mOS were not reached; while the 24-mos PFS and OS rates were 68% and 82%, respectively. After Axi interruption 5 pts were ongoing with avelumab without evidence of PD; 1 discontinued Ave for toxicity after 35.8 mos of maintenance; 2 patients continue Ave alone despite the evidence of PD;21 restarted Axi. Among these 21 pts, after the restart of axitinib, the ORR was 50% (10 pts PR; 8 pts SD; 2 pts PD; 1 pt NA), and the mPFS was 17.2 mos (95%CI, 11.9 – 22.5). Conclusions: Updated results of the TIDE-A study confirmed the feasibility of TKI interruption and IO maintenance in selected mRCC pts after initial response to first line combination of Ave plus Axi. The progression during maintenance with IO alone did not affect the response to the subsequent TKI reintroduction. This strategy warrants further investigation in a randomized trial. Clinical trial information: NCT04698213 .

Digital physiological monitoring for personalized prediction of physical function and fatigue in men with castration sensitive prostate cancer.

Journal of Clinical Oncology Ian Wax, Anneliese Markus, Adele Carlson et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.124

124 Background: Androgen deprivation therapy (ADT) associated fatigue and functional impairment presents challenges to patient quality of life (QOL) and treatment adherence. Clinical features and biomarkers predictive of ADT-associated side effects remain elusive. Objective measures of physical function may have the potential to prognosticate side effects for men with prostate cancer, in particular fatigue. Methods: Men with castration sensitive prostate cancer (CSPC), initiating ADT as monotherapy or in combination with an androgen receptor signaling inhibitor (ARSI), enrolled in this prospective observational study. Patients underwent continuous mobility monitoring for 12 months after ADT initiation. Step count, heart rate and sleep were measured via smartwatch. Fatigue severity and QOL were assessed monthly using the FACIT-Fatigue and FACT-P surveys, respectively. Descriptive statistics and linear mixed modeling were used for analysis. Results: 19 CSPC patients were analyzed: mean age 65.7 years (SD 7.7), 78.9% high risk localized/oligometastatic, 94.7% receiving ADT+radiation with or without an ARSI. Total weekly compliance was 91.6% (SD 5.5%). Average daily baseline step-count was 3,570 (SD 1,881) and declined by 23.9% at 12-months. A statistically weak inverse correlation between step count and fatigue severity was observed (R2=0.075). This prompted further exploratory analysis of individual step count as a predictive measure of physical function. To control for high inter-subject variability, a linear mixed model was used. Individual baseline steps were modeled as a random variable with a mean of 2,782 (SD 1,814; CI [1130.15, 4435.07]; p=0.001). Time on ADT, radiation status, HR and sleep duration were included in this model. Mean daily step count was predicted to decrease by 6.22 steps/week (CI [-10.75, -1.68]; p&lt;.001). Weekly radiation was associated with an average decrease of 275.91 steps (CI [-498.18, -53.32]; p=0.015). Daily and nightly HR was associated with a mean linear increase of 110.98 steps/BPM (CI [88.12, 134.08]; p&lt;0.001) and 100.20 steps/BPM (CI [-122.07, -78.47]; p&lt;0.001), respectively. 1 hour of measured sleep was associated with a decrease of 183.69 steps (CI [-261.98, -104.34]; p&lt;0.001). Overall correlation between actual and predicted step count was 0.88 (R2=0.78). Conclusions: Digital activity monitoring is feasible for men with CSPC on ADT. A weak negative correlation was found between FACIT fatigue severity and average daily step count, while our individualized model accurately predicted daily step count at any point during a 1 year ADT period. While further validation with larger sample sizes is needed, personalized activity predictions may have application in the identification of patients at risk for severe functional impairment, demonstrating value in routine clinical care and clinical trials. Clinical trial information: NCT05390827 .

Identifying engagement strategies for Hispanic youth with anxiety: A youth-centered, Design-Thinking approach

PLoS ONE Thea Runyan, Kristen Hassmiller Lich, Karl Umble et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0317142

Anxiety is the most common and widespread mental health disorder impacting youth between the ages of 10–19. Youth of color including Hispanic youth are disproportionately impacted. Fewer than 20% of youth of color who need mental health services are receiving them. However, we know relatively little about how to best engage Hispanic youth to increase their use of mental health services. The aims of this study were to better understand the personal, environmental, and behavioral factors that impact Hispanic adolescents help-seeking behaviors and to identify the important criteria needed to develop an appealing intervention that would increase engagement with mental health services. This study used a Design Thinking process—a participatory research approach that included qualitative and engaged methods. In-depth interviews (n = 8) and a Design Thinking workshop (n = 11 participants) were conducted with Hispanic youth with anxiety residing in the San Francisco Bay Area. In-depth interviews were coded using Social Cognitive Theory to identify key themes that impact an adolescent’s decision to seek help. The 90-minute workshop included ideation and Design Thinking activities including personas, mind-mapping, and analytical problem-solving to identify the most important tools and strategies that could be used to manage anxiety. The study identified several themes that directly impact program design, including barriers to seeking help for anxiety, coping strategies, sources of support, and specific program ideas. The findings revealed that Hispanic youth want a culturally relevant technology-based program that provides easily accessible educational information and coping strategies delivered in an engaging format that also facilitates mental health support with a trusted adult. The results reinforce the need to develop culturally inclusive and innovative programs designed specifically for priority populations to increase youth engagement with mental health services.

Culture of cryopreserved first trimester placental tissues to study syncytial renewal

Scientific Reports Mary Mansilla, Yao Wang, Guiying Nie Feb 10, 2025 DOI: 10.1038/s41598-025-89022-z

Phase 1 dose escalation (DEs) &amp; expansion (DEx) study to evaluate the safety &amp; efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel).

Journal of Clinical Oncology Charlene Mantia, Chang Gon Kim, Jordi Rodon Ahnert et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps892

Long follow-up quality of life outcomes from an investigator-initiated randomized trial of enzalutamide versus abiraterone plus prednisolone in docetaxel-untreated castration-resistant prostate cancer.

Journal of Clinical Oncology Kouji Izumi, Atsushi Mizokami Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.52

52 Background: Head-to-head comparison between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) demonstrated similar survival benefit for castration-resistant prostate cancer. We analyzed quality of life (QOL) reported over time in each treatment arm as sub-analysis study. Methods: ENABLE study for PCa, an investigator-initiated, multicenter, phase 3 randomized controlled trial, was conducted. FACT-G QOL questionnaires were reported by patients at timepoints. We analyzed questionnaires up to 48 months, including the detailed assessment of subscales which consist of physical, social, emotional, and functional well-being. Results: In total 92 patients in each arm included, 79 and 77 in the ENZ and ABI arm answered questionnaires up to 24 months. There were no significant differences in overall survival and time to PSA progression between arms (P=0.4365 and P=0.2458). Although ENZ did not change the total score of FACT-G during treatment (P=0.8552), ABI significantly deteriorated it gradually (P=0.0002). In ABI arm, the standard dose (1000 mg/day) significantly deteriorated the total score of FACT-G chronologically (n=57, P=0.0002), meanwhile the modified dose (750 mg/day or less) did not change it during treatment (n=15, P=0.1816). In the subscale analysis, ENZ did not deteriorate any subscales, whereas ABI deteriorated social and functional well-beings (P=0.0149 and P=0.0005, respectively). Further dissection of subscale analysis revealed that the modified dose of ABI did not deteriorate social and functional well-beings (P=0.277 and P=0.4026, respectively) but the standard dose of ABI significantly deteriorated them (P=0.0010 and P&lt;0.0001, respectively). Conclusions: A head-to-head comparison of QOL between ENZ- and ABI-treated castration-resistant prostate cancer patients was performed for the first time. ABI deteriorated QOL chronologically and the standard dose of ABI was a main cause of the deterioration in QOL. The modified dose of ABI may be a better treatment option. Clinical trial information: UMIN000015529 .

Association of clinical characterization of renal cell carcinoma (RCC) with merlin protein deficiency and biallelic loss of <i>NF2</i> .

Journal of Clinical Oncology Emre Yekedüz, Marc Machaalani, Stephanie E. Siegmund et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.506

506 Background: Neurofibromin-2 (NF2) is a tumor suppressor gene that encodes the scaffolding protein merlin and is commonly mutated in rare RCC subtypes: unclassified (uRCC), papillary (pRCC), collecting duct carcinoma (CDCA), and the emerging entity, biphasic hyalinizing psammomatous (BHP-RCC). Merlin loss/deficiency by immunohistochemistry (IHC) was recently demonstrated as a reliable surrogate marker of NF2 genomic alterations (GAs). We report the first clinical outcomes of RCC patients (pts) with merlin-deficiency/biallelic loss of NF2, treated with immune checkpoint inhibitor (ICI) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKI) therapies. Methods: In our single institutional cohort, we identified 27 pts with high-grade morphology suggestive of BHP-RCC or unclear subtype. All pts had merlin deficiency (by IHC) and 12/16 pts with genomic data were found to have also had biallelic NF2 loss (by next-generation sequencing). Overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) were evaluated. Survival curves were generated using the Kaplan-Meier method. Results: In the overall cohort (N=27), histologic subtypes included pts with BHP-RCC (N=19), uRCC (N=6), pRCC (N=1), and CDCA (N=1). The median age at diagnosis was 56 and 74.1% (N=20) had metastatic disease. Seventeen pts received systemic treatment and 76.5% (N=13) were treated with ICI-based regimens (Table). In metastatic cohort, median PFS and OS were 4.9 and 24.5 months, respectively. ORR was 28.6% in metastatic pts treated with systemic treatment, with the rate of 18.2% and 66.7% (p=0.18) in those treated with ICI and non-ICI, respectively. Pts treated with ICI and non-ICI had also similar OS (p=0.44), and PFS (p=0.14). In pts with “classic” BPH-RCC morphology who received systemic treatment (N=10), ORR was 25% and median PFS was 4.9 months, while OS did not reach median. In metastatic other merlin-deficient subtypes who received systemic treatment (N=7), ORR was 33.3%, and median PFS and OS were 6.6 and 24.5 months, respectively. No statistically significant differences in ORR (p=1.00), PFS (p=0.93) or OS (p=0.60) were observed between BHP-RCC and other merlin-deficient subtypes. Conclusions: Merlin protein loss by IHC has emerged as a surrogate for biallelic NF2 GAs, which are associated with rare and aggressive RCC subtypes including BHP-RCC. Despite exposure to standard ICI and VEGFR TKI therapies, few pts with merlin deficient RCC derived clinical benefit and prognosis remains poor. Systemic treatment for metastatic disease (n=17). ICINivolumab+IpilimumabNivolumab+Ipilimumab+CabozantinibNivolumab+CabozantinibPembrolizumab+AxitinibAtezolizumab+BevacizumabAtezolizumabNon-ICICabozantinibEverolimusChemotherapy 13 (76.5) 6 (35.2)3 (17.6)1 (5.8)1 (5.8)1 (5.8)1 (5.8) 4 (23.5) 2 (11.7)1 (5.8)1 (5.8)

The systematic techno-stylistic and chemical study of glass beads from post-15th century West African sites

PLoS ONE Miriam Truffa Giachet, Bernard Gratuze, Denis Genequand et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0318588

The systematic chemical analysis of large collections of archaeological glass beads is essential to better understand trade patterns at different times around the world. Glass beads’ trade towards and within sub-Saharan West Africa grew exponentially over time to culminate with the establishment of the Atlantic Trade. Although these artefacts are very commonly found in archaeological contexts dating after the 15th century CE, the assemblages are generally poorly studied from a chemical point of view. We present here the study of 916 glass beads found in five archaeological sites in Ghana, Mali, and Senegal, in contexts dated between the 15th and the mid-20th century CE. Besides the techno-stylistic classification of the whole assemblage, the compositional study of a sub-group of 578 monochrome and polychrome glass beads was performed. The 798 glass samples composing the selected beads were therefore classified based on their main chemical composition. Moreover, major, minor, and trace elements analysis by Laser Ablation-Inductively Coupled Plasma-Mass Spectrometry (LA-ICP-MS) and the statistical analysis of the results by Principal Component Analysis (PCA) led to the identification of the probable origin of the glass. Different suppliers were distinguished for the Ghanaian earlier beads and the Senegalese and Malian later ones, in relation to the different European trade partners at different times.